PetVivo Holdings, Inc.

PetVivo Holdings, Inc. is an emerging biomedical device company that manufactures, commercializes, and licenses innovative medical devices and therapeutics for animals. The company has a pipeline of eighteen products for animals and humans, protected by a portfolio of twelve patents and six proprietary trade secrets covering its biomaterials, products, production processes, and methods of use. PetVivo began commercializing its primary product, Spryng® with OsteoCushion® Technology, in the second quarter of its fiscal year ended March 31, 2022. Spryng® is a veterinarian-administered injection for managing lameness and joint conditions like osteoarthritis in dogs and horses. In August 2021, the company received approximately $9.7 million in net proceeds from a public offering of 2.5 million units at $4.50 per unit. Each unit included one share of common stock and one warrant to purchase one share at an exercise price of $5.625 per share. The common stock and warrants began trading separately on The Nasdaq Capital Market, LLC under symbols "PETV" and "PETVW." Incorporated in March 2009 under Nevada law, the company operates as a single segment from its corporate headquarters in Edina, Minnesota. PetVivo primarily commercializes and licenses products in the veterinary market to treat and manage afflictions in companion animals such as cats, dogs, and horses, leveraging technology initially developed for human biomedical applications.